SecBot SecBot
SECBOTREPLAY Home › Report › AKBA

AKBA · Q3 revenue -37% YoY, net loss

Akebia Therapeutics, Inc. · PRESS-RELEASE filed Nov 5, 2026 at 07:10 ET

At the news

BEARISHIMPACT 5/10

PRESS-RELEASE filed Nov 5, 2026 at 07:10 ET

Akebia reported Q3 2026 total revenue of $36.9M, down 37% YoY from $58.8M, driven by a 53% decline in Auryxia revenue ($20.0M vs $42.5M) due to generic competition. Vafseo net product revenue was $14.8M, roughly flat YoY, with patient growth of 140% YoY but revenue impacted by customer inventory reduction and TDAPA expiration concerns. Net loss was $14.4M vs net income of $0.5M a year ago. Cash position remains strong at $159.3M.

  • Total revenue $36.9M, down 37% from $58.8M YoY
  • Auryxia revenue $20.0M, down 53% from $42.5M YoY due to generic competition
  • Vafseo net product revenue $14.8M, roughly flat from $14.3M YoY
  • Net loss $14.4M vs net income $0.5M YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access